TITLE

Neuropsychiatric Adverse Events With Ritonavir-Boosted Darunavir Monotherapy in HIV-Infected Individuals: A Randomised Prospective Study

AUTHOR(S)
Winston, Alan; Fätkenheuer, Gerd; Arribas, Jose; Hill, Andrew; van Delft, Yvon; Moecklinghoff, Christiane
PUB. DATE
May 2010
SOURCE
HIV Clinical Trials;May/Jun2010, Vol. 11 Issue 3, p163
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Protease inhibitor monotherapy is an attractive treatment option for HIV-infected subjects. Data assessing neuropsychiatric events with the use of protease inhibitor monotherapy are sparse. Methods: Clinician- and patient-reported neuropsychiatric events were assessed over 48 weeks in HIV-infected subjects on stable antiretroviral therapy, with a plasma HIV RNA <50 copies/mL, randomised to commence on a one to one basis darunavir/ritonavir (800/100 mg once daily) alone (DRVrMono) or with nucleoside analogues (DRVrNRTI). Patient-reported events were assessed by the Functional Assessment of HIV Infection (FAHI) questionnaire and included an assessment of cognitive function. Results: Of 256 subjects enrolled, clinician-reported grade 1–4 adverse events of the nervous system (all cause) were seen in 16% of patients in each treatment arm. FAHI questionnaires were completed by 206 subjects at 48 weeks. No differences in cognitive functioning or other FAHI scores were observed between study treatment groups: Cognitive Functioning score [mean (SD)] 8.9 (2.4) and 9.0 (2.6) in DRVrMono arm and 8.8 (2.6) and 8.9 (2.8) in DRVrNRTI arm at baseline and week 48, respectively (P value for difference = .76). Conclusion: In this exploratory analysis, no differences in the evolution of neuropsychiatric adverse events over 48 weeks are observed in HIV-infected subjects randomised to switch antiretroviral therapy to darunavir/ritonavir with or without nucleoside reverse transcriptase inhibitors.
ACCESSION #
53110446

 

Related Articles

  • Description of the L76V Resistance Protease Mutation in HIV-1 B and "Non-B" Subtypes. Charpentier, Charlotte; Lambert-Niclot, Sidonie; Alteri, Claudia; Storto, Alexandre; Flandre, Philippe; Svicher, Valentina; Perno, Carlo-Federico; Brun-Vézinet, Françoise; Calvez, Vincent; Marcelin, Anne-Geneviève; Ceccherini-Silberstein, Francesca; Descamps, Diane // PLoS ONE;Jan2013, Vol. 8 Issue 1, Special section p1 

    Objective: To describe the prevalence of the L76V protease inhibitors resistance-associated mutation (PI-RAM) in relation with patients' characteristics and protease genotypic background in HIV-1 B- and "non-B"-infected patients. Methods: Frequency of the L76V mutation between 1998 and 2010 was...

  • HIV-1 Protease Inihibitors. Eron Jr., Joseph J. // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS160 

    Focuses on the role of protease inhibitors (PI) in the antiretroviral therapy for HIV-1 infected patients. Potent activity in vitro of five United States Food and Drug Administration-approved PI agents; Suppression of HIV-1 replication by PI agents with two nucleoside analogue reverse...

  • Management of the Adverse Effects of Antiretroviral Therapy and Medication Adherence. Max, Blake; Sherer, Renslow // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS96 

    Examines the therapeutic agents included in the highly active antiretroviral therapy (HAART) for the treatment of patients with HIV infections. Link between poor adherence and failure of antiretroviral therapy; Threat of short term-adverse effects to successful introduction and maintenance of...

  • Long-Term Probability of Detecting Drug-Resistant HIV in Treatment-Naive Patients Initiating Combination Antiretroviral Therapy.  // Clinical Infectious Diseases;5/1/2010, Vol. 50 Issue 9, p1275 

    Background. Robust long-term estimates of the risk of development of drug resistance are needed for human immunodeficiency virus (HIV)-infected patients starting combination antiretroviral therapy (cART) regimens currently used in routine clinical practice. Methods. We followed a large cohort of...

  • Compliance and dosage critical in HIV suppression by protease inhibition.  // AIDS Patient Care & STDs;Dec96, Vol. 10 Issue 6, p377 

    Reports that starting and maintaining protease inhibitor therapy at the recommended dosages delays the development of resistant HIV virus and assists in long-term viral suppression. Presentation of indinavir (Crixivan) data.

  • Editorial Response: Discordance between Virological, Immunologic, and Clinical Outcomes of Therapy with Protease Inhibitors among Human Immunodeficiency Virus-Infected Patients. Goetz, Matthew Bidwell // Clinical Infectious Diseases;12/1/1999, Vol. 29 Issue 6, p1431 

    Comments on the findings of I. Mezzaroma, M. Carlesimo, E. Pinter et al on the occurrence of discordant virological and immunologic responses among HIV-infected patients who had received protease inhibitor-based antiretroviral therapy, published in the December 1999 issue of the journal...

  • Ritonavir for advanced HIV infection.  // American Family Physician;7/1/1996, Vol. 54 Issue 1, p372 

    Reports that the United States Food and Drug Administration has approved the protease inhibitor ritonavir for the treatment of patients with human immunodeficiency virus (HIV) infection. Combination of ritonavir with nucleoside analogs or as monotherapy; Clinical trials on the efficacy of...

  • Hyperlipidemia Associated with the Use of Protease Inhibitors. Smith, John H.; Martin, Gregory J.; Decker, Catherine F. // Clinical Infectious Diseases;7/1/2000, Vol. 31 Issue 1, p207 

    Comments on an article by A.D. Roberts, R.A. Muesing, D.M. Parenti, J. Hsia, A.G. Wasserman, G.L. Simon's about alterations in lipid metabolism in HIV-infected patients receiving indinavir. Development of hyperlipidemia with the use of other available protease inhibitors; Lipid profiles of the...

  • HIV Protease Inhibitor--Related Lipodystrophy Syndrome. Carr, Andrew // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS135 

    Explores the association of HIV protease inhibitor (PI) therapy with lipodystrophy syndrome. Occurrence of peripheral lipoatrophy during the course of the therapy; Asymptomatic and nonketotic clinical presentation in diabetes associated with PI therapy; Abnormal lipodystrophy and metabolic...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics